Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RH +19.2%
Other news:
- USO +7.4% (following Israeli strikes on Iranian nuclear sites)
- NEXT +6.5% (finalizes EPC Contract Refresh for Train 4 and executed EPC contract for Train 5)
- CLDX +5.7% (Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025)
- NOG +4.7% (upsizes and prices offering of $175.0 mln of additional 3.625% convertible senior notes due 2029)
- BCRX +3.3% (ORLADEYO (berotralstat) Approved in Colombia)
- FLOC +1.8% (authorizes new $50 mln share repurchase program)
- ATXS +1.8% (reports initial results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress)
- NSC +1.7% (appoints Richard Anderson as chair)
- IMOS +1.3% (adjusts cash dividend distribution ratio to ~NT$1.23 per common share or ~ $0.82 per ADS)